Now available TEZSPIRE™

TEZSPIRE™ (tezepelumab-ekko), subcutaneous injection,  is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.

 

TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus.